Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Mentari Therapeutics (MTRI) Stock Price & Analysis

397 Followers

MTRI Stock Chart & Stats

$15.61$3.41(27.94%)
At close: 4:00 PM EST
$12.5$15$17.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$12.50 - $16.50
52-Week Range
$5.76 - $23.30
Previous Close
$12.20
Volume
N/A
Average Volume (3M)
13.02K
Market Cap
$6.70M
Enterprise Value
$6.30M
Total Cash (Recent Filing)
$1.13B
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
2.96
Next Earnings
Feb 16, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Substantial Financing

The substantial financing provides capital to advance clinical programs and support corporate operations over the coming quarters. It also improves access to public-market funding, potentially giving management greater flexibility to pursue development milestones without relying solely on near-term operating revenue.

Clinical Pipeline

The company has identifiable clinical assets addressing migraine prevention, an area described as having unmet needs. Progressing two related candidates creates potential platform benefits and milestone opportunities, although future value remains dependent on clinical execution and evidence of safety and efficacy.

Minimal Reported Debt

Minimal reported debt reduces recurring interest obligations and avoids the direct refinancing burden associated with heavily leveraged businesses. This can preserve more of any future financing or operating capital for research and development, even though the company’s broader capitalization remains weak.

Bears Say

Persistent Cash Burn

Continued operating and free-cash-flow losses mean the company consumes capital rather than funding development internally. Persistent burn can require additional financing before clinical programs mature, increasing dilution risk and making long-term execution dependent on maintaining access to external capital.

Negative Shareholders’ Equity

Negative shareholders’ equity signals accumulated financial deterioration and reduces balance-sheet resilience. It limits flexibility to absorb setbacks or fund expansion from internal resources, while the sharp change from earlier positive equity indicates that recent losses have materially weakened the company’s capitalization.

Weak And Inconsistent Profitability

Revenue momentum has not translated into a sustainable earnings model: TTM revenue declined, net losses remained substantial, and gross margin weakened. This combination suggests limited operating leverage and makes future financing needs more persistent until the pipeline can generate commercial or partnership income.

Mentari Therapeutics News

MTRI FAQ

What was Mentari Therapeutics’s price range in the past 12 months?
Mentari Therapeutics lowest stock price was $5.76 and its highest was $23.30 in the past 12 months.
What is Mentari Therapeutics’s market cap?
Mentari Therapeutics’s market cap is $6.70M.
When is Mentari Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Mentari Therapeutics overvalued?
According to Wall Street analysts Mentari Therapeutics’s price is currently Undervalued.
Does Mentari Therapeutics pay dividends?
Mentari Therapeutics does not currently pay dividends.
What is Mentari Therapeutics’s EPS estimate?
Mentari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mentari Therapeutics have?
Mentari Therapeutics has 549,374 shares outstanding.
Which hedge fund is a major shareholder of Mentari Therapeutics?
Currently, no hedge funds are holding shares in MTRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology